Reniguard Life Sciences (RLS) is dedicated to improving management of viral diseases and cancers by early detection using cutting edge screening/diagnostic tools.  Early detection is our business and our passion.

 

Our innovative technologies (patent pending) allow ultra-sensitive and quantitative detection of DNA mutations.   We also developed a quantitative methylation detection technique that does not require bisulfite treatment.  We push the limit of early detection  by technical innovations.

 

We collaborate with the leaders of biomarker research and the clinical specialists to develop the highly desired diagnostic/screening tools. 

Copy right ©2010   Reniguard Life Sciences Inc.  All right reserved.

Mission

 

June 2009, RLS received the Technology Commercialization Network (TCN) engagement funding from the Ben Franklin Technology Partners for the development of ultrasensitive mutant quantification technologies to detect the KRas codon 12/13 mutations.

 

October 2009, RLS received engagement funding from the Ben Franklin Technology Partners to develop ultrasensitive mutant quantification technologies for the detection of hepatitis B drug resistance mutant viruses.

 

May 2010, RLS received funding from the Ben Franklin Technology Partners to develop an assay kit for ultrasensitive quantification of the  KRas codon 12/13 mutants for clinical diagnosis and prognosis purposes. 

 

5/19/2010, World Hepatitis Day.  RLS joined a historical rally, organized by the National Viral Hepatitis Roundtable, at Washington DC, to urge the Congress to increase federal funding for chronic viral hepatitis screening, education, and early intervention programs.

News